CD52 and acute lymphoblastic leukemia: In a later trial, adult B- and T-ALL patients that presented more than 10% of CD52+ lymphoblasts were subjected to Alemtuzumab in combination with chemotherapeutic drugs in an effort to eradicate MRD [106].